SCHEMBL18896147

SCHEMBL18896147

CCCCC(CCCC)C(=O)Nc1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
ALDH1A1 P00352 1/20 0.61
MAPT P10636 1/20 0.61
MAPK1 P28482 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
CA1 P00915 3/20 0.58
CA2 P00918 3/20 0.58
CA7 P43166 2/20 0.58
CA14 Q9ULX7 2/20 0.58
LMNA P02545 1/20 0.55
HDAC1 Q13547 3/20 0.54
FAAH O00519 1/20 0.50
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19198292 0.89 SMN1; SMN2 (0.64) MEN1KMT2AALDH1A1MAPTMAPK1
SCHEMBL23454623 0.84 SPHK1 (0.59) MEN1KMT2AALDH1A1MAPTMAPK1
SCHEMBL7099035 0.83 MEN1 (0.78) MEN1KMT2AALDH1A1MAPTMAPK1
SCHEMBL23483310 0.83 SPHK1 (0.54) MEN1KMT2AALDH1A1MAPTMAPK1
SCHEMBL19987448 0.83 MEN1 (0.65) MEN1KMT2AALDH1A1MAPTMAPK1
SCHEMBL18882713 0.83 MEN1 (0.72) MEN1KMT2AALDH1A1MAPTMAPK1
SCHEMBL23271169 0.81 HSD17B10 (0.55) MEN1KMT2AMAPTCA1CA2
SCHEMBL23454659 0.81 EHMT2 (0.54) MEN1KMT2AALDH1A1MAPTMAPK1
Hydrochloric Acid SCHEMBL23271157 0.80 HSD17B10 (0.54) MEN1KMT2AMAPTCA1CA2
SCHEMBL9324598 0.79 MEN1 (0.72) MEN1KMT2AALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11059826-B2 Pteridinone compounds and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-07-13 US disclosed
US-20190322673-A1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2019-10-24 US disclosed
US-9663466-B2 Aryl dihydropyridinones and piperidinone MGAT2 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322673-A1 PTERIDINONE COMPOUNDS AND USES THEREOF DPYD, PKD1, TYMP MEN1 154/4885KMT2A 909/4885ALDH1A1 569/4885
US-11059826-B2 Pteridinone compounds and uses thereof DPYD, PKD1, TYMP MEN1 154/4885KMT2A 909/4885ALDH1A1 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.